In the latest amendment to its Broad Agency Announcement (BAA), BARDA (Biomedical Advanced Research and Development Authority) is seeking proposals for the development of cost-effective and adaptable therapeutic platforms to treat viral infections, as well as next-generation COVID-19 vaccines.
Amendment to BAA Outlines New BARDA Funding Opportunities for Next-generation COVID-19 Vaccines, Monoclonal Antibodies, and Antivirals
